Vast Resources PLC Raises £600,000 Through Placing of Ordinary Shares
Vast Resources PLC Raises £600,000 Through Placing of Ordinary Shares
May 7, 2020
Clear Capital Advisory Account: Its most popular service
July 31, 2020
Show all

Faron Pharmaceuticals Raises EUR14 Million Validating Previous Share Bookbuild

Faron Pharmaceuticals Raises EUR14 Million Validating Previous Share Bookbuild


Recently, Faron Pharmaceuticals, a Finnish company offering drug discovery and development services and focusing on the treatment of acute organ traumas, cancer immunotherapy, and metabolic syndrome vasculopathies, raised EUR14 million in line with a share bookbuild that it had announced previously.

The company further claimed that it expected to raise another EUR10 million through equity issue. Faron Pharmaceuticals revealed that its share issue consisted of 2.7 million Nordic placing shares, with the value of the shares being EUR4.00 per share, an approximately 8% discount on the earlier closing price.

The fundraise also included the issuance of 780,998 UK placing shares, at GBP 3.48 per share. Meanwhile, London-listed shares witnessed a drop of 8.9%, closing at 360.00 pence each.

This is what Markku Jalkanen, Faron Pharmaceuticals CEO, had to say about this recent development: “We are extremely happy with the support we have received from existing and new shareholders on this oversubscribed fundraising. With these additional resources we can expand MATINS cancer cohorts into all nine cancer areas as advised by the trial data monitoring committee recently. With initial clinical benefit already observed among the Part I patients, we are very excited to move to Part II patient recruitment.”

Faron Pharmaceuticals managed to raise funds worth millions with the assistance of Clear Capital Markets Limited (authorised and regulated by the Financial Conduct Authority FRN 706689). If you wish to strengthen the financial position of your entity through similar means, please contact us.

Risk Warning: The value of investments can fall as well as rise; you may not get back the amount invested.

This blog post is written by Bob Roberts, Director at Clear Capital Markets, Fully RDR Compliant (Level 6 / Valid SPS), FSA CF30 Registered, CISI Level 6 Certificate in Private Client Investment Advice & Management (PCIAM), CISI Level 4 Investment, Risk and Taxation (Part of the IAD), CISI Level 3 Certificate in Investments (Derivatives), Unit 1: FSA Financial Regulation (2010),Unit 3 Derivatives (2011)

Areas of expertise:
wealth management, portfolio management, HNW private and professional client relationship management, corporate finance, long/short and hedging strategies, risk management, equities & derivatives.


  1. Avatar dublaj izle says:

    Way cool! Some very valid points! I appreciate you penning this write-up plus the rest of the site is also really good. Lizzie Joshua Danieu

  2. Avatar filmi izle says:

    This is my first time pay a visit at here and i am actually impressed to read everthing at alone place. Dulcine Woodman Loralyn

  3. I am actually grateful to the holder of this web site who has shared this wonderful paragraph at at this place.

  4. Hello there! Would you mind if I share your blog with my myspace group?

    There’s a lot of folks that I think would really enjoy your content.

    Please let me know. Thank you

  5. Avatar yabanci says:

    Good article. I will be experiencing some of these issues as well.. Theodora Keane Rachele

  6. Avatar diziler says:

    Thank you for the auspicious writeup. It in fact was a amusement account it. Look advanced to more added agreeable from you! By the way, how could we communicate? Jenda Florian Horatio

Leave a Reply

Your email address will not be published. Required fields are marked *

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 70% and 80% of Retail investor accounts lose money when trading CFDs on average with our platform providers. You should consider whether you understand how CFDs, FX or any of our other products work and whether you can afford to take the high risk of losing your money. Find out more.